Prime Therapeutics Communications

Prime Therapeutics produces a variety of communications to help keep you apprised of changes and anticipated events in the pharmaceuticals industry.

Drug Recalls and Alerts – recent safety issues from the U.S. Food and Drug Administration (FDA) or clinical studies

• Multaq 07/26/11
• Actos and Bladder Cancer/Chantix and CV Disease 06/21/11
• Zocor (simvastatin), 5 Alpha-Reductase Inhibitors and Victoza 06/14/11
• Vivaglobin Market Withdrawal 04/12/11
• Embeda Recall 03/17/11
• Removal of Unapproved Cough, Cold, Allergy Products from Market 03/09/11
• Availability of OTC Allegra 01/27/11

Pipeline Updates – updates on investigational drugs, specialty drugs, and generic drug issues

• July Pipeline Updates 08/3/11
• June Pipeline Updates 07/07/11
• May Pipeline Updates 05/31/11
• April Pipeline Updates 05/04/11
• March Pipeline Updates 03/31/11
• February Pipeline Updates 02/24/11
• January Pipeline Updates 01/28/11
• December Pipeline Updates 01/3/11

Drug Profile – summarizes the status of a drug that is close to receiving FDA approval, has recently received FDA approval or is a currently marketed drug under FDA review for a new indication for use

• Therapeutic Category Profile on Multiple Sclerosis 07/26/11
• Xarelto 07/21/11
• Cholesterol Category Profile 04/28/11
• Hepatitis C Protease Inhibitors  03/17/11
• Therapeutic Category Profile: Hypertension 02/24/11
• Viibryd Profile 02/16/11

These communications are for informational purposes only and benefit coverage varies.

Prime Therapeutics LLC is a pharmacy benefit management company. Blue Cross and Blue Shield of Texas (BCBSTX) contracts with Prime Therapeutics, a separate company, to provide pharmacy benefit management and other related services. BCBSTX, as well as several other independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.